Browsing Tag
Novo Nordisk A/S
19 posts
Novo Nordisk’s $1.4bn Orbis deal pushes obesity drug race deeper into oral medicines
Novo Nordisk has signed a discovery and licensing agreement worth up to $1.4 billion with Orbis Medicines to develop orally available macrocycle therapies for cardiometabolic disease, extending the Wegovy maker’s strategy beyond injectable GLP-1 drugs and its existing oral semaglutide technology.
Clever Culture Systems (ASX: CC5) wins two more Novo Nordisk APAS orders
Clever Culture Systems Limited has received a purchase order from Novo Nordisk for two additional APAS Independence instruments and a custom laboratory-system integration, moving the pharmaceutical group from evaluation into formal global validation ahead of possible wider deployment.
Novo Nordisk’s $2.1bn Corvidia bet faces impairment after ZEUS trial miss
Ziltivekimab’s Phase 3 failure sends Novo Nordisk down 9%, triggers a Corvidia impairment and weakens its cardiovascular expansion strategy.
MedPal AI raises £5m as MPAL buys eMAR software and backs oral Wegovy launch
MedPal AI is combining pharmacy dispensing, care-home medication software and a private weight-loss clinic, but a 25% share-count expansion raises the execution bar.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Novo Nordisk gets UK nod for single-dose Wegovy 7.2mg pen in obesity care
MHRA has approved the single-dose Wegovy 7.2mg pen for adults with obesity in the United Kingdom. Read what it means for patients and Novo Nordisk.
How direct-to-patient delivery could become the next competitive edge in Europe’s GLP-1 race
Read how Novo Nordisk’s Wegovy delivery update could reshape Europe’s GLP-1 competition, pharmacy economics, and patient access strategy.
Novo Nordisk strengthens obesity leadership with Wegovy HD FDA approval and higher-efficacy profile
Novo Nordisk secures FDA approval for Wegovy HD, boosting weight loss efficacy. Discover what this means for the obesity drug market.
EC backs higher-dose Wegovy as obesity competition intensifies
Novo Nordisk A/S wins EU approval for 7.2 mg Wegovy. Discover how this shifts obesity competition, reimbursement, and long-term strategy.
Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.